Skip to content
FindTrial
Search trials
Search trials by condition, treatment, sponsor...
Sign In
LY2801653
DRUG
2 trials
Sponsors
Eli Lilly and Company
Conditions
Cancer
Healthy
Phase 1
A Study of LY2801653 in Advanced Cancer
Completed
NCT01285037
Eli Lilly and Company
Cancer
Start: 2009-09-09
End: 2017-09-11
Updated: 2018-02-20
A Study of LY2801653 in Healthy Participants Who Are Not Able to Have Children
Completed
NCT02370485
Eli Lilly and Company
Healthy
Start: 2015-02-28
End: 2015-05-31
Updated: 2015-06-19
Related Papers
First-in-Human Phase I Study of Merestinib, an Oral Multikinase Inhibitor, in Patients with Advanced Cancer
The Oncologist
2019-03-04
60 citations
Abstract 2647: Merestinib (LY2801653), targeting several oncokinases including NTRK1/2/3, shows potent anti-tumor effect in colorectal cell line- and patient-derived xenograft (PDX) model bearing TPM3-NTRK1 fusion
Cancer Research
2016-07-15
1 citations
Abstract 4403: Preclinical evaluation of LY2801653, an orally bioavailable small molecule oncokinase inhibitor, in cholangiocarcinoma models
Cancer Research
2014-10-01
2 citations
Abstract CT237: Interim results of a first-in-human phase 1 study of the oral MET kinase inhibitor, LY2801653, in patients with advanced cancer
Cancer Research
2014-10-01
1 citations
LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models.
2012-12-29
124 citations